- Media and supplements
- Stem cells and stem cell-derived cells
Cellartis cardiomyocytes derived from human induced pluripotent stem cells
Cellartis cardiomyocytes are a highly homogeneous population of cardiomyocytes derived from human induced pluripotent stem (iPS) cells (ChiPSC22). The iPS cells have been differentiated into spontaneously beating cardiomyocytes in vitro. These cells have been dissociated into a single-cell suspension and frozen in vials. The Cellartis Cardiomyocytes (from ChiPSC22) Kit contains one vial of cardiomyocytes (>3 x 106 viable cells), one bottle of Cellartis CM Thawing Base, and one bottle of Cellartis CM Culture Base.
Electrophysiological profile highly resembling adult human primary cardiomyocytes
Respond as expected to cardiac stimuli
Derived with a robust, efficient cardiac differentiation protocol, without genetic engineering or selection
Cells are provided with basal medium for thawing and culture
Discovery of novel cardiac drug targets
High-content analysis (HCA)
1 vial Cellartis cardiomyocytes (>3 x 106 viable cells)
1 bottle Cellartis CM Thawing Base (32 ml)
1 bottle Cellartis CM Culture Base (90 ml)
Additional product information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2019 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.